Wnt signalling plays a critical role in the development of cancer. Recent studies indicate that Wnt signalling is negatively regulated by secreted Wnt antagonists such as secreted frizzled related proteins (sFRPs) and Dickkopfs (Dkks). We compared Dkk family expression levels in normal prostate and prostate cancer cells and found a reduction in Dkk-3 expression in cancer cells. Ectopic expression of Dkk-3 inhibited colony formation in LNCaP and PC3 prostate cancer cell lines and inducible expression of Dkk-3 reduced LNCaP cell proliferation. Moreover, small interfering RNAmediated downregulation of Dkk-3 enhanced cell cycle progression in untransformed RWPE-1 prostate epithelial cells. Immunohistochemical analysis revealed that Dkk-3 is expressed in a subset of normal prostate gland acini and that Dkk-3 expression is reduced in prostate tumours, particularly those with a high Gleason grade, suggesting a role for Dkk-3 in postmitotic differentiation. Consistent with this, depletion of Dkk-3 disrupted acinar morphogenesis of RWPE-1 cells in a threedimensional cell culture model. Our results are consistent with the loss of Dkk-3 expression resulting in impairment of glandular structure and uncontrolled prostate epithelial cell (PrEC) proliferation, both of which are crucial for prostate cancer progression.
Introduction
Wnt signalling plays an important role in a wide variety of biological processes including development and carcinogenesis. Wnt ligands interact with frizzled and low-density lipoprotein receptor-related protein 5/6 (LRP5/6) receptors and this leads to activation of the Wnt/b-catenin pathway, also known as the canonical pathway, and the non-canonical planar-cell polarity (Boutros et al., 1998) and Wnt/Ca þ þ pathways (Slusarski et al., 1997) . In the Wnt/b-catenin pathway, stimulation by Wnt ligand induces b-catenin accumulation in the cytoplasm and translocation to the nucleus, where it associates with T cell receptor/lymphoid enhancer factor-1 (TCF/LEF-1) family transcription factors (Behrens et al., 1996; Molenaar et al., 1996) and activates genes involved in cell proliferation such as c-Myc (He et al., 1998) .
Recently, extensive studies have revealed that Wnt signalling is negatively regulated by secreted Wnt antagonists such as secreted frizzled related proteins (sFRPs) (Finch et al., 1997; Leyns et al., 1997; Wang et al., 1997) and Dickkopfs (Dkks) (Mao et al., 2001) . The Dkk family comprises four members, and each possesses an N-terminal signal peptide and contains two conserved cysteine-rich domains separated by a linker region (Krupnik et al., 1999) . Dkk-1 and -2 are known to interact with LRP5/6 (Mao et al., 2001 ) and another transmembrane protein, Kremen (Mao et al., 2002) , selectively inhibiting Wnt/b-catenin pathway by preventing Wnt and frizzled from forming a ternary complex with LRP5/6 and facilitating internalization of these receptors. In terms of development, Dkk-1 is involved in head induction, limb formation, and osteoblast and cardiac myocyte differentiation (for references see Kawano and Kypta, 2003) and Dkk-2 participates in terminal osteoblast differentiation and mineralized matrix formation . Dkk-3 is the most divergent of the Dkk family (Krupnik et al., 1999) . Dkk-3 null mice were recently reported to be viable and fertile, although there were changes in lung ventilation and increased hyperactivity (Barrantes Idel et al., 2006) . The mild phenotype might result from redundancy with Soggy, a Dkk-3-like protein (Krupnik et al., 1999) . Dkk-3 has been shown to be downregulated in various types of cancer and its overexpression can inhibit cell proliferation Hsieh et al., 2004; Kurose et al., 2004; Roman-Gomez et al., 2004b) . Here, we show Dkk-3 is abundantly expressed in hyperplasic normal prostate epithelium and downregulated in high-grade tumours. We also show that changes in Dkk-3 levels affect prostate cell growth and acinar morphogenesis. Our results suggest that Dkk-3 is involved in postmitotic differentiation of prostate epithelial cells (PrECs) and that loss of Dkk-3 could be an important step for prostate cancer progression.
Results
To explore the biological role of Dkks in prostate cancer, reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed to examine the expression level of Dickkopf genes in prostate cancer cell lines and normal PrECs. Expression of Dkk-1 mRNA was found in all prostate cancer cell lines examined, except for LNCaP cells (Figure 1a ). Strong expression of Dkk-2 mRNA was observed in CWR-R1 cells, and weak expression in primary PrEC and LAPC-4 cells (Figure 1a ). Dkk-4 mRNA was barely detectable in all prostate cells examined (data not shown). Interestingly, Dkk-3 mRNA expression was very low in the majority of the prostate cancer cell lines examined, although it was high in primary, non-immortalized PrECs (Figure 1a) . In order to determine if the expression levels were similar at the protein level, culture supernatant from prostate cells was collected and probed for Dkk-3 by Western blotting. This revealed Dkk-3 as a 75 kDa protein that was abundant in the culture supernatant from PrEC cells, but not detectable in the culture supernatant from any of the prostate cancer cell lines examined (Figure 1b) . Although DU145 cells expressed Dkk-3 mRNA, Dkk-3 protein was undetectable in DU145 cells, suggesting post-transcriptional regulation of Dkk-3 in this cell line. These results indicate that Dkk-3 is downregulated in prostate cancer cell lines and suggest that expression of Dkk-3 is inactivated during the process of prostate cancer development.
In order to investigate the effect of Dkk-3 on proliferation of prostate cancer cells, colony formation assays were conducted using LNCaP and PC3 cells transfected with either empty vector or Dkk-3 expression plasmid. Ectopic expression of Dkk-3 significantly reduced the number of colonies formed by both cell lines (Figure 2a ), suggesting that Dkk-3 has an inhibitory effect on prostate cancer cell proliferation.
To investigate further the effect of Dkk-3 on prostate cancer cell proliferation, we established LNCaP/ TR-D3 cells, LNCaP cell sublines expressing Dkk-3 in a doxycycline-inducible manner (Figure 2b ). Western blot analysis showed that Dkk-3 was efficiently secreted into the culture supernatant of LNCaP/TR-D3 cells as early as 6 h after doxycycline induction (Figure 2b ). These cell lines were used to examine the effect of Dkk-3 on prostate cancer cell proliferation. Proliferation of LNCaP/TR-D3 cells was suppressed upon doxycline induction in a time-dependent manner, whereas there was no effect of doxycycline on proliferation of LNCaP/TR2 cells, which expressed only the tetracycline repressor (Figure 2c ). Thus, Dkk-3 inhibits prostate cancer cell proliferation.
We next considered the possibility that loss of Dkk-3 expression might be sufficient to increase proliferation of untransformed PrECs. Here, we used RWPE-1 cells, which are an immortalized cell line derived from normal adult human PrECs . RWPE-1 cells, like PrEC cells, secrete Dkk-3 protein ( Figure 3a) ; their advantage over PrEC cells is that they are more amenable to transfection. To assess the effect of depleting endogenous Dkk-3, RWPE-1 cells were transfected with control or Dkk-3 small interfering RNA (siRNAs). RT-PCR of RNA and Western blot analysis of culture supernatant indicated that the siRNAs for Dkk-3 effectively reduced Dkk-3 expression in RWPE-1 cells (Figure 3a) . To analyse the role of Dkk-3 in cell proliferation, BrdU incorporation assays were conducted to estimate the effects of loss of Dkk-3 expression on the G1/S transition. As shown in Figure 3b , RWPE-1 cells transfected with two different Dkk-3 siRNAs showed increased BrdU incorporation compared to pooled control siRNA-or GL2-luciferase siRNA-transfected cells (Figure 3b, left Dkk-3 in prostate cell growth and morphogenesis Y Kawano et al cells, which revealed a reduced G1 phase population and an elevated S phase population in Dkk-3 siRNAtransfected cells (Figure 3b , right). Thus, endogenous Dkk-3 inhibits prostate cell proliferation by negatively regulating the G1/S transition. Although Dkk family members were first identified as regulators of the Wnt signalling pathway (Glinka et al., 1998) , there are conflicting reports on whether Dkk-3 affects Wnt/b-catenin signalling (Krupnik et al., 1999; Tsuji et al., 2000; Caricasole et al., 2003; Hoang et al., 2004) . Therefore, we determined whether the negative effect of Dkk-3 on prostate cell proliferation correlated with any effects on Wnt/b-catenin signalling. Cytoplasmic b-catenin, which is a hallmark of activation of the Wnt/b-catenin pathway, was detectable in both LNCaP/ TR and LNCaP/TR-D3 cells, suggesting Wnt/b-catenin signalling in these cells is already active (Figure 4a ), possibly because LNCaP cells already express some canonical Wnts . However, doxycycline induction of Dkk-3 expression did not alter the cytoplasmic level of b-catenin in LNCaP/TR-D3 cells (Figure 4a ). We also measured the activity of a TCF/ LEF-responsive luciferase reporter in these cells and found that induction of expression of Dkk-3 had no significant effect on b-catenin/TCF-dependent transcription (Figure 4b ). These results indicate that Dkk-3 does not affect Wnt/b-catenin signalling in LNCaP cells and suggest that the effect of Dkk-3 on proliferation is independent of Wnt/b-catenin signalling.
The finding that Dkk-3 has an inhibitory effect on prostate cancer cell proliferation prompted us to determine whether Dkk-3 expression is downregulated in human prostate cancer samples. First, we performed conventional immunohistochemistry to demonstrate (c) 2 Â 10 5 cells were plated in 6 cm dishes and cultured for a further 48 h. Then, 1 mg/ml doxycycline was added as appropriate. Cells were collected by trypsinization at the indicated times and were counted using a haemocytometer. Cell number was expressed as the average7s.d. of duplicate cultures.
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Dkk-3 expression in both normal and cancer tissue. As both PrEC and RWPE-1 cells, which originate from prostate epithelium, express Dkk-3, we expected expression of Dkk-3 in epithelium of adjacent normal prostate gland overall. Interestingly, fewer than half of the prostate glands exhibited positive staining in PrECs (see Supplementary Information Figure A ). In these prostate glands, the staining pattern was heterogeneous: in general, positive staining was observed in both luminal and basal cells; however, there was a tendency that luminal cells were stained more strongly than basal cells ( Figure 5A , a and b. arrow: luminal cell, arrowhead: basal cell). In luminal cells, although staining was distributed throughout the cytoplasm, the apical side of the cell showed stronger staining than the basal side ( Figure 5A , a and b). In addition, a stronger staining pattern of Dkk-3 was observed in prostate glands with multilayered hyperplastic luminal cells than in those with single-layered luminal cells ( Figure 5A , b). Dkk-3 was also found to be expressed in ganglion cells (see Supplementary Information Figure B ). Mesenchymal cells such as fibroblasts and smooth muscle cells did not appear to express Dkk-3 ( Figure 5A , a and b, data not shown). When we examined prostate cancer samples, we found only weak or no staining of Dkk-3 overall in the tumour cells ( Figure 5A , c).
In order to investigate the relationship between Dkk-3 expression and clinico-pathological parameters in prostate cancer, Dkk-3 expression was examined in a prostate cancer tissue microarray (TMA). Immunohistochemical analysis of the TMA revealed highly variable expression of Dkk-3. Almost all the samples contained some Dkk-3-positive tumour cells ( Figure 5A , d-g), with the number of positive cells ranging from 1.3 to 100% (median value: 37.4%). Interestingly, the percentage of cells expressing Dkk-3 was inversely correlated with Gleason grade (Figure 5A, . Statistical analysis indicated that expression of Dkk-3 is significantly reduced in cancers with a Gleason score of 9 or 10 compared to those with a score of Gleason 8 or below ( Figure 5C ). Analysis of microarray data from two independent studies (Dhanasekaran et al., 2001; Lapointe et al., 2004 ) supports these observations, revealing a significant decrease in expression of Dkk-3 in advanced prostate tumours (RM Kypta, unpublished observations). There was no correlation between Dkk-3 expression and age or tumour stage. These results suggest that Dkk-3 is downregulated in prostate Dkk-3 in prostate cell growth and morphogenesis Y Kawano et al tumours with poor glandular structure and imply that Dkk-3 is involved in prostate gland differentiation.
To test the hypothesis that Dkk-3 is involved in prostate gland differentiation, we utilized a threedimensional (3D) in vitro model of human prostate acinar formation using RWPE-1 cells. RWPE-1 cells undergo acinar-like morphogenesis with spherically arranged polarization and both structural and functional differentiation when grown in a 3D Matrigel environment (Bello-DeOcampo et al., 2001b) . When RWPE-1 cells were transfected with control GL2-luciferase siRNA, they organized themselves into distinct acini 4 days after plating on Matrigel ( Figure  6A , a), similar to non-transfected cells (data not shown). In contrast, RWPE-1 cells transfected with Dkk-3 siRNA developed either smaller-sized acini compared to control siRNA-transfected cells ( Figure 6A , b and 6B) or non-polarized amorphous cell aggregates ( Figure  6A , b arrows and 6C). These results indicate that endogenous Dkk-3 is required for acinar morphogenesis and support the hypothesis that Dkk-3 plays a role in prostate gland differentiation.
Discussion
Dkk-3 is downregulated in various type of cancer, including non-small-cell lung carcinoma (Tsuji et al., 2000; Nozaki et al., 2001) , acute lymphoblastic leukemia (Roman-Gomez et al., 2004a) hepatocellular carcinoma (Hsieh et al., 2004) , and renal cell carcinoma (Kurose et al., 2004) . Although the Dkk-3 gene is localized on chromosome 11p15 where loss of heterozygocity in human cancers is often observed (Tsuji et al., 2000) , several lines of evidence have shown that Dkk-3 downregulation in cancers is owing to promoter hypermethylation (Kobayashi et al., 2002; Lodygin et al., 2005) . Our work and recent reports from other groups have shown that Dkk-3 overexpression inhibits tumour cell proliferation Hsieh et al., 2004) . Taken together, these observations suggest that Dkk-3 can be regarded as a tumour suppressor. The expression of Dkk-3 was found to be downregulated in most of the prostate cancer cell lines examined and ectopic expression of Dkk-3 had an inhibitory effect on prostate cancer cell proliferation in growth and colony formation assays. Moreover, abrogated expression of Dkk-3 by siRNA transfection advanced the G1/S transition in untransformed PrECs. The role of Dkk-3 in G1/S transition was also suggested by Tsuji et al. (2001) , who showed that ectopic expression of Dkk-3 inhibits tritiated thymidine incorporation in SaOS-2 cells and that Dkk-3 is downregulated in accordance with the G1/S transition in KMS-6 cells.
It remains unclear whether Dkk-3 acts as a direct Wnt antagonist. Unlike Dkk-1, Dkk-3 does not interact with LRP5/6 (Mao et al., 2001) , and overexpression of Dkk-3 does not have any effect on axis duplication induced by XWnt-8 (Krupnik et al., 1999; Mao et al., 2001) or on TCF/LEF reporter activity in 293 cells (Krupnik et al., 1999) . Tsuji et al. (2000) also reported that Dkk-3 overexpression does not affect nuclear/cytoplasmic accumulation of b-catenin. On the other hand, Caricasole et al. (Figure 4a and b) , LNCaP/TR-D3 cells were exposed to abundant Dkk-3 for at least 18 h before harvesting cells. Therefore, it is unlikely that Dkk-3 contributes to the inhibition of cell proliferation in a manner similar to Dkk-1. Taken together with the previous reports mentioned above, these results suggest that the effect of Dkk-3 on Wnt/b-catenin signalling is dependent on cellular context and that Dkk-3 is involved in the inhibition of prostate cancer proliferation via a Wnt/b-catenin-independent pathway.
An additional observation we made regarding the biological activity of Dkk-3 is that the effect of Dkk-3 on cell proliferation became apparent only 5 days after Dkk-3 induction (day 7 in Figure 2c ). One possibility is that Dkk-3 affects cell proliferation in a density- Dkk-3 in prostate cell growth and morphogenesis Y Kawano et al dependent manner. Hsieh et al. (2004) reported that suppression of growth of HeLa, Hep3B and Huh 7 cells by Dkk-3 was attenuated as cell density increased. Although the effect observed differs from that in prostate cancer cells, the implication is that the function of Dkk-3 is somehow linked to cell density. Further investigation to identify Dkk-3 receptors will be required to clarify the biological role of Dkk-3 in prostate cancer development. We also examined the patterns of expression of Dkk-3 in human prostate cancer and adjacent normal prostate epithelium using conventional tissue sections and TMA. Interestingly, analysis of the normal prostate tissue revealed that Dkk-3 was expressed in PrECs in a subset of prostate glands. Heterogeneous, zonal expression of Dkk-3 has also been reported in other organs (Suwa et al., 2003; Byun et al., 2005) . In addition, we found that Dkk-3 was more highly expressed in prostate glands with hyperplastic but otherwise normal prostate epithelium than in prostate glands with a single-layered epithelium, suggesting Dkk-3 is abundantly expressed in proliferative normal epithelium. Byun et al. (2005) reported a similar observation in the colon, where Dkk-3 is expressed strongly at the base of colon crypt, which contains proliferating epithelial precursor cells. These observations are paradoxical to the finding that Dkk-3 is a negative regulator of PrEC proliferation. Interestingly, Waltregny et al. reported a similar paradox regarding expression of p27, a cyclin-dependent kinase inhibitor, in rat prostate. They showed that androgen replenishment after castration, which induces regeneration of the prostate, triggers upregulation of p27 in PrECs. They hypothesized that p27 may limit the proliferation of PrECs to favour their postmitotic differentiation (Waltregny et al., 2001) .
In our examination of Dkk-3 expression in prostate tumour cells, we found that Dkk-3 was downregulated in high-grade prostate cancers. Analysis of microarray data from two independent studies (Dhanasekaran et al., 2001; Lapointe et al., 2004) using web-based freeware (http://www.oncomine.org) supports these observations, revealing a significant decrease in the expression of Dkk-3 in advanced prostate tumours (unpublished observations). In addition, during the preparation of this manuscript Lodygin et al. (2005) reported that the promoter of Dkk-3 is methylated in 68% of prostate cancer tumours, and Abarzua et al. (2005) reported that Dkk-3 expression is significantly reduced in tumours with a Gleason score of 8 and above. The latter report differs from our results, as we only found a statistically significant reduction in expression in tumours with a Gleason score of 9 and above. The difference might result from using different methods of analysis: we determined the proportion of Dkk-3-expressing cells, whereas Abarzua et al. used imaging software to calculate overall signal intensity.
The reduced expression of Dkk-3 in high-grade tumours, where glandular structure is severely disorganized, suggests that Dkk-3 is involved in postmitotic polarization and/or differentiation of PrECs and facilitates maintenance of glandular structure in the normal prostate gland. The loss of Dkk-3 expression in prostate cancer would then be predicted to impair glandular polarization and/or differentiation, which are crucial for prostate cancer progression. We tested this hypothesis using the RWPE-1 3D acinar morphogenesis model . Reduction of Dkk-3 expression in RWPE-1 cells resulted in a decrease in acinar size and a failure of acinar formation, suggesting that Dkk-3 is important for acinar development and/or differentiation. There are a number of crucial events necessary for normal acinar formation, including growth factor stimulation (Hoffman et al., 1996; Bello-DeOcampo et al., 2001b) , cell-matrix interactions (Hoffman et al., 1996; Bello-DeOcampo et al., 2001a; Naylor et al., 2005) and cell-cell interactions (Hoffman et al., 1996; Menko et al., 2002) . Experiments are underway to determine which of these is altered upon depletion of Dkk-3.
To summarize, we have used overexpression studies and siRNA-mediated depletion to show that Dkk-3 affects the proliferation of prostate cancer cells and normal prostate cells. We have also shown that Dkk-3 levels are significantly reduced in advanced prostate tumours where gland morphology is severely disrupted. Finally, we have shown that depletion of Dkk-3 disrupts acinar morphogenesis in untransformed PrECs. Taken together, these results suggest that Dkk-3 normally promotes postmitotic differentiation of the prostate gland and that loss of Dkk-3 contributes to disruption of gland morphogenesis, an important step in prostate cancer progression.
Materials and methods

Cells
The cell lines used were obtained from American Type Culture Collection (Rockville, MD, USA), except for LAPC-4 cells obtained from Charles Sawyers (UCLA, Los Angeles, CA, USA) and CWR-R1 cells obtained from Christopher Gregory (University of Carolina at Chapel Hill, Chapel Hill, NC, USA). Foetal bovine serum (FBS), charcoal-stripped serum (CSS), antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin) and cell culture media were purchased from Invitrogen (Paisley, UK) or Sigma (Gillingham, UK). LAPC-4 cells were grown in Iscove's modified Dulbecco's modified Eagle's medium (DMEM) containing 15% FBS and 10 nmol/l R1881. CWR-R1 cells were grown in Richter's improved minimum essential medium (MEM) containing 10 mmol/l nicotinamide, 20 ng/ml epidermal growth factor (EGF), 5 mg/ml insulin, 5 mg/ ml transferrin, 5 ng/ml selenium and 2% FBS. LNCaP, DU145 and PC-3 cells were grown in RPMI 1640 containing 10% FBS. PrEC (Cambrex Cork Ltd, Cork, Ireland, UK) were grown in PrEC growth medium (Cambrex Bio Science, Nottingham, UK). RWPE-1 cells were grown in keratinocyte serum-free medium (SFM) supplemented with bovine pituitary extract and EGF (Invitrogen). Hans Clevers (Hubrecht Laboratory, Utrecht, The Netherlands). pOT-luc is from Bert Vogelstein and Ken Kinzler (Johns Hopkins University, Baltimore, MD, USA). For the generation of pCS2-hDkk-3 (without Flag tag), N-and C-terminal halves of hDkk-3 were obtained from pCS2-hDkk-3-Flag and pCMV-Tag3-Dkk-3 (encoding the 2440 bp EcoRI-XhoI fragment from IMAGE clone 3916954, a generous gift from Maria Vivanco, CIC Biogune, Bilbao, Spain), respectively. For the generation of pcDNA4/TOhDkk-3, hDkk-3 cDNA in pCS2-hDkk-3 was shuttled to pcDNA4/TO-luc.
Reagents
Anti-hDkk-3 goat polyclonal antibody was purchased from R&D systems (Abingdon, UK). Anti-g-tubulin monoclonal antibody was purchased from Sigma. Anti-b-catenin monoclonal antibody and fluorscein isothiocyanate (FITC)-conjugated anti-5-bromo-2 0 -deoxyuridine (BrdU) monoclonal antibody were purchased from BD biosciences (Oxford, UK). R1881 was purchased from DuPont-NEN (Boston, MA, USA).
RT-PCR
RT-PCR was performed as described previously . In brief, total RNA from cell lines was extracted with Trizol reagent according to the manufacturer's instructions (Invitrogen), and reverse transcription was performed using Superscript II (Invitrogen) and 5 mg of total RNA from cultured cells. PCR amplification was carried out using Taq polymerase (Promega) as per the manufacturer's instructions. Sequences of primer pairs for Dickkopfs are as follows: Dkk-1, forward primer 5 0 -ACTGCAAAAATGGAATATGTGTGT-3 0 and reverse primer 5 0 -TTCTAGTCCATGAGAGCCTTTTC T-3 0 ; Dkk-2, forward primer 5 0 -TCAGAAAATTTGATCACC ATTGAG-3 0 and reverse primer 5 0 -GTAATTTCCACTGT GTGCTTGTTC-3 0 ; Dkk-3, forward primer 5 0 -ACCGAGAA ATTCACAAGATAACCA-3 0 and reverse primer 5 0 -AGTCC CTCTGGTTGTCACAGAT-3 0 ; and Dkk-4, forward primer 5 0 -ACAAGAGGGAGAAAGTTGTCTGAG-3 0 and reverse primer 5 0 -TTTTGCAATGTGGATTCTTCTTTA-3 0 . Sequence of primers for b-actin was described previously . PCR was performed for 35 cycles (Dickkopfs) or 30 cycles (b-actin) under the following conditions: 941C for 30 s, 601C for 30 s and 721C for 30 s. For confirmation of abrogation of Dkk-3 expression by siRNA in RWPE-1 cells, a forward primer for Dkk-3 was used that flanks the putative siRNA cleavage site (Huppi et al., 2005) :
Western blotting
Western blotting was performed as described previously . In brief, for total cell extracts, cells were rinsed in cold phosphate-buffered saline (PBS) and lysed in modified radioimmunoprecipitation assay (RIPA) buffer (0.5% deoxycholate, 1% Triton X-100, 20 mM Tris, pH 8.0, 0.1% sodium dodecyl sulphate (SDS), 100 mM NaCl, 50 mM NaF). For analysis of soluble b-catenin, cytoplasmic extracts from LNCaP/TR cells and LNCaP/TR-D3 cells were generated by hypotonic lysis . To detect endogeneous hDkk-3, 10 cm dish of cells were rinsed once with PBS and then grown for 48 h in opti-MEM (Invitrogen). The supernatant was centrifuged to remove cell debris and added to 50 ml StrataClean Resin (Stratagene, La Jolla, CA, USA). Resin-bound proteins were pelleted by centrifugation and resuspended in SDS sample buffer. Loading volume was normalized by the expression of g-tubulin in the corresponding cell lysates. Western blots were probed using antibodies at 1:1000.
Colony formation assay Cells (6 Â 10 5 ) of LNCaP cells or PC3 cells were plated in a 10 cm dish and transfected with 5 mg of pcDNA4/TO-empty plasmid or pcDNA4/TO-hDkk-3 using Tfx-50 (Promega). Three days later, transfected LNCaP cells and PC3 cells were selected with 500 or 75 mg/ml Zeocint (Invitrogen), respectively. Three weeks later, colonies were visualized by crystal violet staining.
Generation of stable cell lines
The T-REx system (Invitrogen) was used according to the manufacturer's instructions to generate LNCaP cell lines that inducibly express Dkk-3. LNCaP cell lines expressing the Tet repressor were generated by transfection with pcDNA6/TR expression plasmid and selection with resistance to 12 mg/ml blasticidin (Invitrogen). Colonies were expanded and doxycycline inducibility was estimated by luciferase assay after transient transfection with pcDNA4/TO-luc. Subclones showing both highly inducible and non-leaky expression of luciferase were chosen, and one of these was named LNCaP/TR2. LNCaP/TR2 cells were re-transfected with pcDNA4/TOhDkk-3 and selected with resistance to both 6 mg/ml blasticidin and 300 mg/ml Zeocint (Invitrogen). Positive clones (LNCaP/ TR-D3 cells) were identified by Western blotting for hDkk-3.
Cell proliferation assay 2 Â 10 5 cells were plated in 6 cm dishes in RPMI 1640 containing 10% faetal calf serum and 6 mg/ml blasticidin (day 0). Cells were cultured for a further 48 h and 1 mg/ml doxycycline was added where appropriate. The media were changed at days 5 and 7. Cells were collected by trypsinization at the indicated times and were counted using a haemocytometer. Cell number was expressed as the average7s.d. of duplicate cultures. Experiments were repeated three times, and the most representative results are shown.
siRNA transfection, FACS analysis and BrdU incorporation assays siRNA transfections (Elbashir et al., 2001) were carried out according to the manufacturer's protocol using Oligofectamine reagent (Invitrogen). RWPE-1 cells were seeded into six-well plates and grown for 48 h before transfection. The sequences of the siRNAs were as follows: human Dkk-3, 5 0 -ACACGAAGG UUGGAAAUAA-3 0 (Dkk-3 1; corresponding to nucleotides 302-320 relative to the start codon) or 5 0 -CACGAAGGUUG GAAAUAAU-3 0 (Dkk-3 2; nucleotides 303-321) according to the criteria proposed by Reynolds et al. (2004) . As siRNA controls, control pooled siRNA (kind gift from Simak Ali, Imperial College London, UK) and siRNA targeting GL2-luciferase at positions 153-175 were used. All siRNAs were obtained from MWG BIOTECH (Ebersberg, Germany). At 48 h after transfection, cells were trypsinized and replated to both another six-well plate to monitor Dkk-3 depletion and a 6 cm dish for assay. After 24 h, cells were deprived of both bovine pituitary extract and EGF for another 24 h, followed by the re-addition of medium containing these supplements and 10 mM BrdU (Sigma) for 30 min. Cells were then trypsinized, washed twice in PBS, washed once in 0.5% bovine serum albumin/PBS and fixed overnight at 41C in 70% ethanol. After fixation, the cells were stained with FITC-conjugated antiBrdU antibody and propidium iodide as reported previously (Gamble et al., 2004) . Fluorescence-activated cell sorting (FACS) analysis was carried out using a Beckton-Dickinson FACSCantot Flow cytometer and FACSDiva software. A total of 10 000 events were measured per sample.
Immunohistochemisty
Human prostate cancer and adjacent normal prostate were obtained from prostate cancer patients who underwent radical prostatectomy at the Kumamoto Central Hospital. Local Research Ethics Committee approval was obtained and patients provided written informed consent. Samples were formalin-fixed, paraffin-embedded and dissected for immunohistological analysis. Representative haemotoxylin-eosinstained sections were examined to evaluate the histopathologic characteristics of the lesion to be analysed. A TMA consisting of 55 specimens of resected prostate cancer (CA2) was purchased from SuperBioChips Lab. (Seoul, South Korea). The pathological information of the patients is available on this company's web site (http://www.tissue-array.com/ver3/). As the Gleason grades of the tumour spots were not provided by the manufacturer, they were independently regraded by a pathologist (MMW). The embryonal rhabdomyosarcoma sample was excluded from the analysis. Sections were deparaffinized and rehydrated using graded alcohol concentrations. Antigen retrieval was performed by incubation in 10 mM sodium citrate (pH 6.0) and heating in a microwave oven at 560 W for 8 min. Endogeneous peroxidase was quenched by 3.0% H 2 O 2 for 5 min. After nonspecific binding was blocked with 10% horse serum for 20 min, sections were incubated with goat anti-human Dkk-3 (AF1118, R&D systems, Abingdon, UK) at a 1:200 dilution for 30 min at room temperature. Bound primary antibody was visualized using Vectastain Elite ABC Standard kit (Vector Labs, Burlingame, CA, USA) according to the manufacturer's instructions. In TMA analysis, the number of Dkk-3 cytoplasm-positive cancer cells and the total number of cancer cells in three random fields ( Â 400) per each spot were counted, and the number of Dkk-3-positive cells per one hundred prostate cancer cells was defined as Dkk-3 expression. The median value of Dkk-3 expression was 37.4%, and spots below the median were defined as low expressors and others as high expressors. This approach has been used previously by others for assessing levels of expression (Cheng et al., 2000; Halvorsen et al., 2003) . Statistical analysis was performed by Mann-Whitney U-test.
Acinar morphogenesis assay
The 3D culture of RWPE-1 cells on Matrigel was carried out according to Debnath et al. (2003) with minor modifications. Briefly, eight-well glass chamber slides (Nunc) were coated with 40 ml of Phenol Red-free BD Matrigelt (BD Biosciences) per well, referred to here as Matrigel. At 24 h after transfection with siRNAs, RWPE-1 cells were trypsinized and resuspended in Keratinocyte SFM with complete supplements. Five thousand cells were plated per well in assay medium (keratinocyte SFM with complete supplements and 2% Matrigel). Assay medium was replaced every 2 days. Pictures were obtained by using Axiovert S 100 microscope (Zeiss) equipped with COOLPIX 5000 digital camera (Nicon). The experiment was repeated four times and a representative result is shown.
